Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant M-VAC + Avastin in Locally Advanced Urothelial Cancer
NCT00506155Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2007
- Primary completion
- Aug 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in urothelial carcinoma (UC), sponsored by University of Texas MD Anderson Cancer Center. Started Jun 2007; status: completed.
02
Drugs
bevacizumab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT00506155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00506155.